Clinical Data From Full Phase 1 Cohort of Investigational Sotorasib Published in New England Journal of Medicine

NSCLC Data Featured in Proffered Presentation Session at Virtual ESMO 2020

Manuscript Represents First Phase 1 Results Published for a KRASG12C Inhibitor

MISSISSAUGA, ON, Sept. 22, 2020 /CNW/ – Amgen has announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumours, were published in the New England Journal of Medicine (NEJM). Data from 59 patients with advanced non-small cell lung cancer (NSCLC) reported in the NEJM manuscript were also featured during an oral presentation at ESMO 2020. Please note the safety and efficacy of sotorasib is still under investigation and market authorization has not been obtained.

“We are pleased to present the updated Phase 1 results of CodeBreaK 100, the largest Phase 1/2, and first-in-human, clinical study for a KRASG12C inhibitor,” said Dr. Suna Avcil, executive

Read More